UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K WESBANCO, INC. (Exact name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of Incorporation) West Virginia 001-39442 55-0571723 (Commission File Number) (IRS Employer Identification No.) 1 Bank Plaza Wheeling, West Virginia 26003 (Address of Principal Executive Offices) (Zip Code) Registrant's Telephone Number, Including Area Code: 304 234-9000 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securi ...

Core Insights - MongoDB's Atlas has become a central pillar of the company's platform strategy, with strong adoption across various industries, including notable customers like CSX and LG Uplus [1] - The company reported total revenues of $549 million in the fiscal first quarter, marking a 22% year-over-year increase, with Atlas revenues growing 26% and accounting for 72% of total revenues [2] - MongoDB anticipates continued growth from Atlas, reflected in its raised revenue guidance for fiscal 2026, projected at $2.25–$2.29 billion [3] Revenue and Customer Growth - In the fiscal first quarter, Atlas customer count reached over 55,800, up from 47,700 a year ago, indicating strong customer acquisition [2] - The Zacks Consensus Estimate for MongoDB's subscription revenues for the fiscal second quarter is $537.5 million, with an estimated customer count of approximately 55,863 for Atlas [3] Strategic Initiatives - To support future growth, MongoDB is focusing on application modernization and AI, including the acquisition of Voyage AI and plans to enhance user capabilities [4] - The company is investing in developer training, certifications, and self-serve tools to drive greater adoption of Atlas [4] Competitive Landscape - MongoDB faces increasing competition from Amazon's DynamoDB and Couchbase, both enhancing their offerings in the cloud database market [5][6] - Amazon's DynamoDB has introduced multi-region strong consistency, improving its reliability for applications [5] - Couchbase has launched a new version of its cloud database designed for AI agent workflows, supporting real-time systems [6] Stock Performance and Valuation - MongoDB shares have declined by 8.7% year-to-date, underperforming the Zacks Internet – Software industry growth of 14.3% [7] - The stock is currently trading at a forward Price/Sales ratio of 6.89X, compared to the industry's 5.74X, indicating a higher valuation [11] - The Zacks Consensus Estimate for second-quarter fiscal 2026 earnings is 64 cents per share, reflecting an 8.57% year-over-year decline [15]

来源：央视新闻 乌沙科夫还称，两国领导人今天没有就举行会晤的可能性进行讨论，双方会晤的问题仍然悬而未决。 3日稍早时，俄罗斯总统普京表示，当日其将与美国总统特朗普通电话。当天，美国总统特朗普也表 示，他将于美东时间当日上午10点（北京时间22时）与俄罗斯总统普京通话。 此前曾有媒体报道，在7月4日美国"独立日"到来之际，俄美两国总统将通电话。 泽连斯基：若要实现和平俄乌领导人直接会晤不可或缺 当地时间7月3日，乌克兰总统泽连斯基在丹麦哥本哈根举行的新闻发布会上表示，若要实现俄乌之间的 和平，乌克兰与俄罗斯领导人之间的直接会晤不可或缺。 俄美元首通话约1小时讨论中东局势、俄乌谈判等 当地时间7月3日，俄罗斯总统助理乌沙科夫表示，俄总统普京与美总统特朗普的通话结束，通话持续了 约一小时。他表示，普京与特朗普的谈话"在同一频率上"，谈话务实且具体。 乌沙科夫表示，普京在与特朗普的通话中指出，俄罗斯愿意继续与乌克兰的谈判进程。乌沙科夫还称， 特朗普在与普京的通话中提出了尽早结束对乌克兰军事行动的问题。 乌沙科夫表示，普京与特朗普今日通话中未涉及美国停止对乌武器供应这一议题。双方也没有讨论俄乌 伊斯坦布尔第三轮谈判的具 ...

Core Viewpoint - Rocket Pharmaceuticals, Inc. is facing a class action lawsuit due to allegations of providing misleading information regarding its clinical trials, particularly concerning the safety of its gene therapy product RP-A501 for Danon disease [3][4]. Group 1: Lawsuit Details - The class action lawsuit is titled Ho v. Rocket Pharmaceuticals, Inc. and covers purchasers of Rocket Pharmaceuticals securities from February 27, 2025, to May 26, 2025 [1]. - The lawsuit alleges that Rocket Pharmaceuticals and a top executive violated the Securities Exchange Act of 1934 by concealing material adverse facts about the safety and clinical trial protocol of RP-A501 [3]. - It is claimed that the company failed to disclose serious adverse events, including the death of a participant, which occurred after a protocol amendment that introduced a new immunomodulatory agent [3][4]. Group 2: Impact on Stock - Following the announcement of a clinical hold by the U.S. Food and Drug Administration on May 27, 2025, due to a serious adverse event, Rocket Pharmaceuticals' stock price experienced a decline [4]. Group 3: Legal Process - Investors who purchased Rocket Pharmaceuticals securities during the class period can seek appointment as lead plaintiff in the lawsuit, which allows them to act on behalf of other class members [5]. - The lead plaintiff can choose a law firm to represent the class, and participation as lead plaintiff does not affect the ability to share in any potential recovery [5]. Group 4: About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [6]. - The firm has been ranked 1 in the ISS Securities Class Action Services rankings for four out of the last five years, indicating its strong track record in obtaining monetary relief for investors [6].

Core Insights - Monte Rosa Therapeutics has published significant findings in Science, revealing how its AI/ML technology expands the targetable protein space for molecular glue degraders, potentially addressing previously undruggable therapeutic targets [1][2]. Company Overview - Monte Rosa Therapeutics is a clinical-stage biotechnology company focused on developing highly selective molecular glue degrader (MGD) medicines for serious diseases, including oncology and autoimmune conditions [3]. - The company utilizes its proprietary QuEEN™ discovery engine, which integrates AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to design MGDs with unprecedented selectivity [3]. Research and Development - The recent research highlights the ability of Monte Rosa's QuEEN discovery engine to identify over 100 new protein targets that are amenable to degradation, many of which are currently considered inaccessible to small molecule binding [2]. - The findings significantly broaden the therapeutic reach of Monte Rosa's pipeline, particularly in immunology, inflammation, and oncology, where the company is advancing clinical programs [2]. Strategic Collaborations - Monte Rosa has established a global license agreement with Novartis to develop VAV1-directed molecular glue degraders and a strategic collaboration with Roche to discover MGDs targeting cancer and neurological diseases previously deemed impossible to drug [3].

两年期美债收益率涨9.51个基点，报3.8799%，日内交投于3.7517%-3.9089%区间，本周累涨13.20个基 点。 周四（7月3日）纽约尾盘，美国10年期基准国债收益率上涨6.89个基点，报4.3457%，全天呈现出工字 形走势，整体交投于4.2475%-4.3576%区间，北京时间20:30发布美国非农就业报告时从4.26%一线飙升 至接近4.36%的水平，本周（迄今）累计上涨6.89个基点。 ...

金十数据7月4日讯，希腊克里特岛东南部一处森林7月2日发生严重山火。3日，又有4个村庄的居民被要 求立即撤离。消防部门称，该地区的火势仍未得到有效控制，消防员仍在继续灭火。目前，事发地周边 约5000名游客被转移至安全地带。据悉，希腊民防部门已增派消防力量前往支援。 希腊克里特岛发生山火 约5000名游客被转移 ...

来源：央视新闻 俄美元首通话约1小时 讨论中东局势、俄乌谈判等 当地时间7月3日，俄罗斯总统助理乌沙科夫表示，俄总统普京与美总统特朗普的通话结束， 通话持续了约一小时。他表示， 普京与特朗普的谈话"在同一频率上"，谈话务实且具体。 此前曾有媒体报道，在7月4日美国"独立日"到来之际，俄美两国总统将通电话。 乌沙科夫表示， 普京在与特朗普的通话中指出， 俄罗斯愿意继续与乌克兰的谈判进程 。乌 沙科夫还称， 特朗普在与普京的通话中提出了尽早结束对乌克兰军事行动的问题。 据乌克兰最高拉达（议会）官方网站当地时间7月3日消息，乌克兰总统泽连斯基签署修订 《预算法典》的法案， 允许将矿产开采资金转入乌克兰—美国重建投资基金。 乌沙科夫表示，普京与特朗普今日通话中未涉及美国停止对乌武器供应这一议题。双方也没 有讨论俄乌伊斯坦布尔第三轮谈判的具体日期。乌沙科夫称，在与特朗普的通话中，普京强 调了通过政治和外交手段解决中东问题的重要性。乌沙科夫表示 ，必要时可在24小时内组织 新一轮两国元首通话。 乌克兰当地时间5月1日，乌第一副总理兼经济部长斯维里坚科在社交媒体上透露，根据乌克 兰总统弗拉基米尔·泽连斯基与美国总统唐纳德· ...

报告指出，现代电商平台的角色，已从单纯的交易场所转型为消费者信任 的管理者。尤其在如Shopee Mall这类平台中，消费者可以集中选购官方品牌， 享有15天退货保证与价格保护等服务，大大增强了购物信心。 2025年上半年，泰国消费者购物过程中不仅更节省，而且更理性。他们虽 然花更少时间比价，但对透明度和服务质量要求更高，更容易被"更可靠的选 择"所吸引。这对所有电商平台与线上卖家而言是一场"服务深度"的竞赛，谁 能更快满足理性与情感的双重需求，谁就能赢得长期忠诚度。 调查数据显示，64%的消费者更在意商品品质与商家可信度，而非单纯低 价；超过70%的消费者追求高性价比，强调购物过程中的信任感。这意味着， 购物早已不知是价格战，消费者在下单时会综合考量从产品选择、物流配送到 售后服务的每一个环节，最终决定是否"物有所值"。 特别是在城市人群中，购物速度成为关键因素。当前消费者更倾向于"立 即拥有"，而非"等待折扣"，这促使电商平台持续优化配送效率、保障政策与 用户体验。例如电商平台Shopee推出"全、值、快、保障"的购物理念，强化热 卖精选、价格保障与快速配送功能，精准响应了消费者"讨厌等待"的心理。 （原 ...

Group 1: Company Strategies - Roku is adopting a platform-first strategy focused on connected TV ads and user-friendly interface, while Disney leverages its content library and streaming bundles to create a comprehensive ad-supported streaming experience [1][2] - Roku's platform revenues increased by 17% year over year to $881 million, with a gross margin of 52.7%, and streaming hours on The Roku Channel rose by 84% year over year [4][10] - Disney is enhancing its ad-supported streaming market position by integrating Hulu and sports content into Disney+, which has led to increased engagement and reduced churn [7][8] Group 2: Performance Metrics - Roku's The Roku Channel became the 2 app by engagement in the U.S. in Q1 2025, with over a third of U.S. streaming households engaging monthly [3][4] - Disney's streaming business saw a 20% year-over-year increase in adjusted earnings in Q2 2025, with ESPN's primetime viewership among the 18-49 demographic up 32% year over year [8][11] - Roku's Home Screen reaches over 125 million people daily, while Disney is preparing a fully bundled experience combining live sports and entertainment [5][8] Group 3: Market Trends and Challenges - Advertiser demand is shifting towards non-guaranteed programmatic campaigns, putting pressure on Roku's platform margins [6][10] - Disney is investing in ad-tech and personalization to improve user engagement and advertising ROI, with major platform improvements expected soon [9][10] - Roku faces near-term challenges due to reliance on programmatic ads, while Disney benefits from a unified platform and rising engagement [20][21] Group 4: Valuation and Stock Performance - Disney shares are trading at a forward Price/Sales ratio of 2.23X, while Roku's is at 2.62X, indicating that DIS shares are undervalued compared to ROKU [12] - Year-to-date, Roku shares have gained 19.5%, while Disney shares have appreciated 11% [14] - Earnings estimates show Roku's second-quarter 2025 loss is expected at 17 cents per share, while Disney's earnings are pegged at $1.47 per share, indicating a better outlook for DIS [17][20]